Findings show promise for developing potential new anti-inflammatory drugs and treatments for autoimmune diseases.
Étiquette : GlycoNet
GlycoNet partner company, Alectos Therapeutics, enters ground-breaking $700 million agreement with Biogen
This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders.
Glycomics is writing the next chapter in bioinnovation
In BIOTECanada’s Insights Magazine, GlycoNet Scientific Director Warren Wakarchuk writes about the importance of glycomics, opportunities to leverage glycomics, and Canadian glycomics expertise.
Molecules with anti-inflammatory, restorative properties could be key to tackling neurodegenerative disease
GlycoNet researchers are studying a group of molecules that could provide insight into treating and monitoring neurodegenerative diseases.
New research reveals clues to how antibodies get fine-tuned to fight infection
Scientists discover a cellular mechanism that may yield insights into improving vaccines and better understanding cancer and autoimmune diseases.
De nouvelles ressources éducatives renforcent la confiance dans les vaccins et la maîtrise de l'information
GlycoNet a reçu une subvention PromoScience du CRSNG et s'est associé au Centre d'éducation en mathématiques, sciences et technologie pour développer des ressources que les éducateurs peuvent utiliser pour enseigner la science derrière les vaccins et impliquer les élèves dans la pensée critique.
New treatment could reduce tissue damage in Duchenne muscular dystrophy patients by as much as 50 per cent
A carbohydrate-derived drug shows promise as a treatment to slow progression of the most common form of muscular dystrophy.
Op-ed: Glycomics is the new frontier in bioinnovation
Read about the future of glycomics in this op ed by GlycoNet board chair Karimah Es Sabar, republished from the Hill Times. Canada has a tremendous opportunity with continued investment in glycomics to establish global leadership and economic prosperity while at the same time solving some of the world’s most pressing challenges in health and environmental sustainability.
La glycomique : La nouvelle frontière de la bioinnovation
In our new report: Why glycomics, the study of sugars on cells, is at the centre of a new surge of scientific and industry interest.
Making strides in Alzheimer’s research
GlycoNet researchers have made exciting advances in understanding Alzheimer’s disease and are developing a potential therapeutic strategy.